SG11202006441SA - Agents and methods for predicting response to therapy - Google Patents

Agents and methods for predicting response to therapy

Info

Publication number
SG11202006441SA
SG11202006441SA SG11202006441SA SG11202006441SA SG11202006441SA SG 11202006441S A SG11202006441S A SG 11202006441SA SG 11202006441S A SG11202006441S A SG 11202006441SA SG 11202006441S A SG11202006441S A SG 11202006441SA SG 11202006441S A SG11202006441S A SG 11202006441SA
Authority
SG
Singapore
Prior art keywords
therapy
agents
methods
predicting response
predicting
Prior art date
Application number
SG11202006441SA
Other languages
English (en)
Inventor
Sudha Rao
Original Assignee
Epiaxis Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018900108A external-priority patent/AU2018900108A0/en
Application filed by Epiaxis Therapeutics Pty Ltd filed Critical Epiaxis Therapeutics Pty Ltd
Publication of SG11202006441SA publication Critical patent/SG11202006441SA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/10—Post-translational modifications [PTMs] in chemical analysis of biological material acylation, e.g. acetylation, formylation, lipoylation, myristoylation, palmitoylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11202006441SA 2018-01-15 2019-01-15 Agents and methods for predicting response to therapy SG11202006441SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018900108A AU2018900108A0 (en) 2018-01-15 Proteinaceous molecules and uses therefor
AU2018900392A AU2018900392A0 (en) 2018-02-08 “agents and methods for predicting response to therapy”
PCT/AU2019/050025 WO2019136532A1 (en) 2018-01-15 2019-01-15 Agents and methods for predicting response to therapy

Publications (1)

Publication Number Publication Date
SG11202006441SA true SG11202006441SA (en) 2020-08-28

Family

ID=67218185

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006441SA SG11202006441SA (en) 2018-01-15 2019-01-15 Agents and methods for predicting response to therapy

Country Status (8)

Country Link
US (1) US20210055302A1 (ja)
EP (1) EP3740756A4 (ja)
JP (1) JP7236164B2 (ja)
CN (1) CN111936857B (ja)
AU (1) AU2019207535B2 (ja)
CA (1) CA3087779A1 (ja)
SG (1) SG11202006441SA (ja)
WO (1) WO2019136532A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4284949A1 (en) * 2021-01-28 2023-12-06 Ariel Scientific Innovations Ltd. Setdb1-microtubule interaction and use thereof
CN113109565B (zh) * 2021-04-12 2024-02-02 中国人民解放军空军军医大学 一种评估患者对pd-1单抗产品敏感性的检测盒及其应用
CN117999357A (zh) * 2021-06-14 2024-05-07 波士顿大学董事会 用于检测细胞应激的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013166118A2 (en) * 2012-05-02 2013-11-07 New York University Methods related to cancer treatment
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
EP3082840B1 (en) * 2013-12-20 2021-03-24 The General Hospital Corporation Methods and assays relating to circulating tumor cells
US9856315B2 (en) * 2014-10-15 2018-01-02 Cell Signaling Technology, Inc. Methylation and acetylation sites
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
KR102610592B1 (ko) * 2015-03-30 2023-12-07 주식회사 에스티큐브 당화 pd-l1에 특이적인 항체 및 그의 사용 방법
SG11202006459XA (en) * 2018-01-15 2020-08-28 Epiaxis Therapeutics Pty Ltd Proteinaceous molecules and uses therefor

Also Published As

Publication number Publication date
US20210055302A1 (en) 2021-02-25
JP2021510833A (ja) 2021-04-30
EP3740756A4 (en) 2021-10-27
WO2019136532A1 (en) 2019-07-18
CN111936857B (zh) 2024-04-16
CN111936857A (zh) 2020-11-13
AU2019207535B2 (en) 2021-12-23
EP3740756A1 (en) 2020-11-25
CA3087779A1 (en) 2019-07-18
JP7236164B2 (ja) 2023-03-09
AU2019207535A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
IL269462B (en) mdm2 inhibitors and therapeutic methods using them
HK1246304A1 (zh) 包含抗cd73抗體和a2a受體抑制劑的治療組合及其用途
IL271025A (en) Multibiotic substances and methods of using them
IL258332A (en) Antibody factors specific for human differentiation group 19 and their uses
IL258931A (en) Medicinal compounds and methods
GB201709456D0 (en) Therapeutic agents
IL282794A (en) therapeutic method
ZA201504902B (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
SG11202102255VA (en) Methods and systems for therapeutic agent analysis
IL290908A (en) A platform for the discovery and analysis of therapeutic substances
IL273252A (en) Preparations and methods for predicting response to NAPI2B-targeted therapy
GB201521357D0 (en) Methods for predicting response to anti-TNF therapy
EP3534910A4 (en) THERAPEUTICS AND PROCEDURES
EP3378462C0 (en) WEARABLE VEST FOR THE APPLICATION OF PULMONARY THERAPY AND ASSOCIATED PROCEDURES
GB201805816D0 (en) Therapeutic agents
SG11202006441SA (en) Agents and methods for predicting response to therapy
IL270011B (en) Medicinal compounds and methods
SG11202108707WA (en) Methods and agents for assessing t-cell function and predicting response to therapy
GB201700553D0 (en) Therapeutic agents
IL269817A (en) Medicinal cells in macrocapsules and methods of using them
GB201709186D0 (en) Construction block and methods of use
AU2018900392A0 (en) “agents and methods for predicting response to therapy”
GB201819936D0 (en) Therapeutic methods
GB201811467D0 (en) Therapeutic agents
GB201800639D0 (en) Therapeutic agents